Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Solid Tumor 1

Interventions

pembrolizumab 26Cisplatin 15Pemetrexed 14Paclitaxel 14Carboplatin 14Nivolumab 10Cyclophosphamide 10Docetaxel 8atezolizumab 7Injections 7Melphalan 6tislelizumab 5olaparib 5Gemcitabine 5Filgrastim 5durvalumab 4aldesleukin 4Leucovorin 4Irinotecan 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bevacizumab 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3defactinib 3adavosertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Poly(ADP-ribose) Polymerase Inhibitors × Other solid neoplasm × Clear all
NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
31 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡